Compare HP Inc (HPQ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Organon & Co. Common Stock — how do they compare? HP Inc trades at $30.18 (market cap $27.47B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: HP Inc is far larger — about 7.6× Organon & Co. Common Stock's market cap, and HP Inc pays the higher dividend (3.94%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Organon & Co. Common Stock for 0 Days on average.
| HPQ | OGN | |
|---|---|---|
Market Cap | $27.47B | $3.61B |
Volume | 11,226,290 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $35.48 | $13.81 |
52-Week Low | $18.20 | $5.70 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $33.64B | $11.03B |
Dividend Yield | 3.94% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.63, up 2.54% today, with a bearish technical signal but oversold short-term RSI. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is projected to grow to $59.2B in 2026, though net margins are compressing. The company maintains strong cash flow, funding a 3.82% dividend yield, but faces headwinds from a forecasted mid-single-digit decline in PC sales for 2027.
The outlook is mixed: valuation appears attractive with a P/E of 11.63 and P/S of 0.48, and consistent earnings beats provide support. However, negative shareholder equity and a cautious PC market outlook from UBS and company guidance present significant risks. Analyst consensus is divided, with a hold-heavy rating and a $25.75 price target below the current price, suggesting limited near-term upside amid sector challenges.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
